PE20091560A1 - Comprimido de desintegracion oral - Google Patents

Comprimido de desintegracion oral

Info

Publication number
PE20091560A1
PE20091560A1 PE2009000311A PE2009000311A PE20091560A1 PE 20091560 A1 PE20091560 A1 PE 20091560A1 PE 2009000311 A PE2009000311 A PE 2009000311A PE 2009000311 A PE2009000311 A PE 2009000311A PE 20091560 A1 PE20091560 A1 PE 20091560A1
Authority
PE
Peru
Prior art keywords
found
weight
parts
dispersion
disintegration tablet
Prior art date
Application number
PE2009000311A
Other languages
English (en)
Inventor
Hidekazu Okazaki
Naoki Kamada
Masafumi Toda
Tadashi Fukami
Haruka Koizumi
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of PE20091560A1 publication Critical patent/PE20091560A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA EN FORMA DE COMPRIMIDO DESINTEGRANTE ORAL, QUE COMPRENDE: A) CILOSTAZOL Y SACARIDOS TALES COMO MANITOL, XILITOL, ENTRE OTROS EN FORMA DE PARTICULAS GRANULADAS QUE SE PREPARAN POR DISPERSION UNIFORME DE UNA SUSTANCIA INORGANICA Y UN AGENTE DESINTEGRANTE, DONDE (a) LOS SACARIDOS SE ENCUENTRA EN 40-90 PARTES EN PESO, (b) LA SUSTANCIA INORGANICA SE ENCUENTRA EN 1-30 PARTES EN PESO Y (c) EL AGENTE DESINTEGRANTES SE ENCUENTRA EN 5-40 PARTES EN PESO; B) UN DESLIZANTE TAL COMO DIOXIDO DE SILICIO HIDRATADO, ACIDO SILICICO ANHIDRO LIVIANO Y PESADO, QUE SE ENCUENTRA EN UNA CANTIDAD DE 0.2% A 2% (p/p); C) UN EXCIPIENTE ORGANICO TALES COMO ALMIDON DE MAIZ, CELULOSA CRISTALINA, ENTRE OTROS; D) UNO O MAS ADITIVOS OPCIONALES TALES COMO LUBRICANTES, EDULCORANTES, AROMATIZANTES, ENTRE OTROS. DICHO COMPRIMIDO ES UTIL PARA PACIENTES DE EDAD AVANZADA Y PACIENTES QUE SUFREN DE DISFAGIA
PE2009000311A 2008-02-29 2009-02-27 Comprimido de desintegracion oral PE20091560A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2008050460 2008-02-29

Publications (1)

Publication Number Publication Date
PE20091560A1 true PE20091560A1 (es) 2009-10-30

Family

ID=40718911

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000311A PE20091560A1 (es) 2008-02-29 2009-02-27 Comprimido de desintegracion oral

Country Status (7)

Country Link
EP (1) EP2262487A2 (es)
JP (1) JP2011513194A (es)
AR (1) AR070530A1 (es)
CL (1) CL2009000452A1 (es)
PE (1) PE20091560A1 (es)
TW (1) TW200936184A (es)
WO (1) WO2009107864A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011158110A2 (en) 2010-04-28 2011-12-22 Nuformix Limited Cilostazol cocrystals and compositions
ES2422657B1 (es) * 2012-02-10 2014-06-11 Laboratorios Normon S.A. Composición farmacéutica sólida de cilostazol
CN104487094B (zh) 2012-07-20 2017-05-17 大塚制药株式会社 表面具有干燥油墨被膜的片剂、及用于喷墨打印机的油墨
EP3023109A4 (en) 2013-07-19 2017-01-04 Sanwa Kagaku Kenkyusho Co., Ltd Orally disintegrating tablet
US9974738B2 (en) 2013-09-27 2018-05-22 Daicel Corporation Disintegrating particle composition produced by two-stage wet granulation process, and intraorally disintegrating tablet containing same composition
US10231914B2 (en) * 2015-06-02 2019-03-19 Lynette Batton Effervescent tablet for elimination of red wine discoloration, offensive odour of mouth and cleaning the palate
EP3409294A1 (en) 2017-06-01 2018-12-05 Przedsiebiorstwo Farmaceutyczne Lek-Am Sp Z O. O. Tablets containing cilostazol of specific particle size distribution

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548490B1 (en) * 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
JP4802436B2 (ja) * 2000-04-12 2011-10-26 Ｍｓｄ株式会社 口腔内崩壊型組成物及び口腔内崩壊型製剤
JP4637338B2 (ja) * 2000-09-22 2011-02-23 大塚製薬株式会社 シロスタゾール有核錠
JP4551627B2 (ja) * 2003-02-28 2010-09-29 東和薬品株式会社 口腔内崩壊錠剤の製造方法
US8647668B2 (en) * 2003-10-15 2014-02-11 Fuji Chemical Industry Co., Ltd. Tablet quickly disintegrating in oral cavity
JP3841804B2 (ja) * 2003-10-15 2006-11-08 富士化学工業株式会社 口腔内速崩壊性錠剤用の組成物
TWI383809B (zh) * 2005-06-29 2013-02-01 Otsuka Pharma Co Ltd 含有西洛他唑（ｃｉｌｏｓｔａｚｏｌ）之口腔崩解粉末
WO2007029376A1 (ja) * 2005-09-02 2007-03-15 Fuji Chemical Industry Co., Ltd. 口腔内速崩壊性錠剤

Also Published As

Publication number Publication date
EP2262487A2 (en) 2010-12-22
TW200936184A (en) 2009-09-01
JP2011513194A (ja) 2011-04-28
CL2009000452A1 (es) 2010-03-26
WO2009107864A2 (en) 2009-09-03
WO2009107864A3 (en) 2009-12-03
AR070530A1 (es) 2010-04-14

Similar Documents

Publication Publication Date Title
PE20091560A1 (es) Comprimido de desintegracion oral
PE20142305A1 (es) Compuestos de n-ariltriazol como antagonistas de lpar
PE20142440A1 (es) Composiciones farmaceuticas orales de liberacion inmediata con recubrimiento no enterico que comprende 5-azacitidina
CL2012003211A1 (es) Compuestos derivados de lactamas sustituidas con piperidinilo, moduladores de gpr119; proceso para preparar los compuestos; composicion farmaceutica que comprende a los compuestos; y uso de los compuestos en la preparacion de medicamentos para el tratamiento o prevencion de diabetes tipo 2, obesidad y condiciones relacionadas
CL2011003072A1 (es) Compuestos derivados de 4´-(isoxazol-5-il)-bifenil-4-il-cicloalquil(c3-8), antagonistas del receptor de acido lisofosfatidico; composicion farmaceutica que los comprende; y sus usos en el tratamiento del cancer, problemas pulmonares, entre otras.
PE20090185A1 (es) Formulaciones farmaceuticas que contienen un inhibidor sglt2
AR094548A1 (es) Dispersión sólida físicamente estable
PE20100050A1 (es) Forma de dosificacion farmaceutica para la liberacion inmediata de un derivado de indolinona
EA201390332A1 (ru) Дейтерированные аналоги придопидина, применимые в качестве допаминергических стабилизаторов
PE20121517A1 (es) Compuestos lipopeptidos y metodos relacionados
EA201071288A1 (ru) Тризамещенные пиразолы в качестве модуляторов рецепторов ацетилхолина
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
PE20130481A1 (es) Composiciones farmaceuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona
UA104869C2 (uk) Фармацевтичні композиції, що містять ліганди рецептора дофаміну
CO6331308A2 (es) Derivados de carboxamidaindazol con actividad sobre el receptor cb1 y composiciones farmaceuticas que los comprenden
CU24619B1 (es) Letermovir amorfo y formulaciones farmacéuticas sólidas del mismo para administración por via oral
EA201300539A1 (ru) Твердая композиция для приема внутрь (варианты), способ терапевтической или нетерапевтической профилактики желудочно-кишечных расстройств или поддержания здорового состояния желудочно-кишечного тракта с ее помощью (варианты) и упаковка, ее содержащая
CY1118057T1 (el) Φαρμακευτικη συνθεση για στοματικη χορηγηση
CO6630178A2 (es) Nuevos comprimidos de meloxicam de baja concentración
EA201500375A1 (ru) Композиция для ухода за ротовой полостью
TN2015000135A1 (en) Modified release formulations for oprozomib
MX344846B (es) Combinacion de granulos cargados activos con activos adicionales.
PE20121131A1 (es) Composicion farmaceutica oral solida en comprimido monocapa que comprende irbesartan y besilato de amlodipina
MX338156B (es) Formulaciones topicas de tipo suspension que comprenden depsipeptido ciclico.
PE20080673A1 (es) Formulaciones orales liofilizadas de desintegracion rapida de un antagonista del receptor de trombina

Legal Events

Date Code Title Description
FD Application declared void or lapsed